Calliditas Therapeutics AB

Calliditas Therapeutics AB

Health CarePharmaceuticals & Biotechnology
  • Price (SEK)83.00
  • Today's Change0.00 / 0.00%
  • Shares traded29.54k
  • 1 Year change81.62%
  • Beta--
Data delayed at least 15 minutes, as of Apr 08 2020 14:09 BST.
More ▼

Profile data is unavailable for this security.

About the company

Calliditas Therapeutics AB, formerly Pharmalink AB, is a Sweden-based specialty pharmaceutical company. It is focused on the development and commercialization of its product candidate Nefecon, a treatment for patients with inflammatory kidney disease (IgA nephropathy) who are at risk of progressing to renal failure. Nefecon is derived from the TARGIT technology, in which the capsule containing the active drug substance is coated in a way that the capsule remains intact as it passes through the stomach and intestine until it reaches the lower small intestine, where the release of content takes place. Nefeco combines time lag effect with a concentrated release of the active substance budesonide, within a designated target area.

  • Revenue in SEK (TTM)184.83m
  • Net income in SEK-32.58m
  • Incorporated--
  • Employees14.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Surgical Science Sweden AB101.52m12.60m1.88bn58.00175.044.5767.7818.551.561.5617.7359.730.36533.007.17--4.531.825.042.1682.3394.5212.413.222.67------54.5128.95378.7854.94----
Orexo AB844.80m219.20m1.97bn127.009.202.857.562.336.166.1623.7719.900.60610.69163.396,651,969.0015.733.5023.785.0687.5079.5325.955.502.3684.910.32770.007.888.1858.88---14.91--
Hofseth Biocare ASA66.25m-87.21m2.42bn43.00--20.69--36.51-0.2889-0.28890.22130.36350.28191.556.701,576,256.00-37.10-44.69-52.63-73.9927.4722.61-131.63-162.221.45-20.190.5294--11.5927.94-5.25--14.83--
Immunovia AB (publ)357.00k-114.52m2.52bn49.00--7.04--7,047.12-5.85-5.850.018218.190.0008--22.027,285.71-25.54-20.15-26.86-21.09-14,355.18-8,695.51-32,078.71-21,999.36---424.710.0954--7.04-0.1771-32.34--63.06--
Oasmia Pharmaceutical AB844.00k-197.13m2.92bn62.00--4.27--3,457.74-0.6549-0.65490.00261.610.0012-0.02030.396314,066.67-27.39-27.77-33.84-43.44137.20346.37-23,356.87-5,370.332.55-15.950.1109---37.52101.23-71.08---19.54--
Calliditas Therapeutics AB184.83m-32.58m3.21bn14.00--4.08--17.38-0.7567-0.75675.0020.360.2475--5.34---4.36---4.62-------17.63-----6.25--------75.33------
Oriola Oyj18.84bn88.67m3.49bn2.82k42.431.956.380.18510.03980.03989.490.86661.766.159.37610,823.300.82872.812.799.0920.7321.510.47061.640.39923.210.502274.7010.891.32-25.93-29.67-6.14--
Hansa Biopharma AB3.36m-360.01m3.80bn74.00--6.75--1,128.56-9.00-9.000.084114.060.0042--0.296645,459.46-44.75-38.19-49.93-41.5574.2685.18-10,701.84-4,954.36----0.0178--0.178715.76-45.18--23.28--
Orphazyme A/S0.00-494.86m4.15bn86.00--39.54-----16.87-16.870.002.65------0.00-------------------47.700.5836-------46.99------
Data as of Apr 08 2020. Currency figures normalised to Calliditas Therapeutics AB's reporting currency: Swedish Krona SEK

Institutional shareholders

31.38%Per cent of shares held by top holders
HolderShares% Held
Max Mitteregger Kapitalf�rvaltning ABas of 30 Sep 20192.35m6.08%
Fj�rde AP-fondenas of 30 Sep 20192.11m5.45%
Handelsbanken Fonder ABas of 01 Apr 20202.11m5.44%
BVF Partners LPas of 30 Sep 20191.87m4.82%
AFA Sjukf�rs�kringsaktiebolag (Invt Mgmt)as of 30 Sep 20191.64m4.24%
Swedbank Robur Fonder ABas of 28 Feb 2020545.30k1.41%
Fidelity Management & Research Co. LLCas of 31 Dec 2018517.32k1.34%
C Worldwide Asset Management Fondsm�glerselskab A/S (Sweden)as of 31 Dec 2018392.25k1.01%
Xact Kapitalf�rvaltning ABas of 29 Feb 2020315.17k0.81%
Andra AP-fondenas of 31 Dec 2019300.00k0.78%
More ▼
Data from 31 Dec 2016 - 01 Apr 2020Source: FactSet Research Systems Inc.
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.